Rep. Val T. Hoyle Sells GSK PLC Sponsored ADR (NYSE:GSK) Shares

Representative Val T. Hoyle (D-Oregon) recently sold shares of GSK PLC Sponsored ADR (NYSE:GSK). In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in GSK stock on September 23rd. The trade occurred in the Representative’s “FIDELITY ROLLOVER IRA” account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marriott International (NASDAQ:MAR) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of H&R Block (NYSE:HRB) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of NIKE (NYSE:NKE) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Bank of New York Mellon (NYSE:BK) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Cisco Systems (NASDAQ:CSCO) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Pentair (NYSE:PNR) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Heico (NYSE:HEI.A) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Target (NYSE:TGT) on 9/23/2025.

GSK Stock Performance

NYSE:GSK opened at $43.53 on Friday. The stock’s fifty day moving average is $40.33 and its 200 day moving average is $38.85. The firm has a market capitalization of $88.55 billion, a PE ratio of 20.15, a PEG ratio of 1.96 and a beta of 0.53. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $45.59.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.GSK’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 9th. Investors of record on Friday, August 15th were issued a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 3.9%. The ex-dividend date was Friday, August 15th. GSK’s dividend payout ratio is presently 78.24%.

Institutional Investors Weigh In On GSK

Several hedge funds have recently bought and sold shares of the stock. Twin Peaks Wealth Advisors LLC acquired a new stake in GSK in the second quarter valued at approximately $25,000. HHM Wealth Advisors LLC boosted its stake in GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 460 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of GSK in the 1st quarter valued at $31,000. Richardson Financial Services Inc. lifted its stake in shares of GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock valued at $33,000 after purchasing an additional 472 shares during the last quarter. Finally, SOA Wealth Advisors LLC. lifted its stake in GSK by 252.1% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 605 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

GSK has been the topic of a number of recent research reports. Weiss Ratings reissued a “hold (c)” rating on shares of GSK in a research report on Wednesday. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Seven analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $37.38.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon’s 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon’s 4th Congressional District. She declared candidacy for the 2026 election.

Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.